Tumors escape immunosurveillance by overexpressing the proteasome activator PSME3.

Antigen Presentation Histocompatibility Antigens Class I Monitoring, Immunologic Proteasome Endopeptidase Complex / genetics Tumor Escape
Tumor immune responses activator PSME3 pioneer translation products proteasome regulations

Journal

Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526

Informations de publication

Date de publication:
21 05 2020
Historique:
entrez: 14 9 2020
pubmed: 15 9 2020
medline: 15 9 2020
Statut: epublish

Résumé

The success of CD8

Identifiants

DOI: 10.1080/2162402X.2020.1761205 PMID: 32923122 PMC: PMC7458623
pubmed: 32923122
doi: 10.1080/2162402X.2020.1761205
pii: 1761205
pmc: PMC7458623
doi:

Substances chimiques

Histocompatibility Antigens Class I 0
Proteasome Endopeptidase Complex EC 3.4.25.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

1761205

Informations de copyright

© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.

Références

Cell Cycle. 2009 Aug;8(15):2399-407
pubmed: 19556897
Int J Clin Exp Pathol. 2014 Oct 15;7(11):7834-43
pubmed: 25550823
Br J Cancer. 2014 Jan 21;110(2):353-62
pubmed: 24281003
J Mol Cell Biol. 2010 Aug;2(4):192-8
pubmed: 20494959
Med Oncol. 2011 Mar;28(1):31-41
pubmed: 20467919
J Cell Biol. 2006 Nov 6;175(3):401-13
pubmed: 17088425
Nat Struct Biol. 2000 Nov;7(11):1062-7
pubmed: 11062564
J Biol Chem. 1999 Dec 31;274(53):38211-5
pubmed: 10608895
J Biol Chem. 1999 Feb 5;274(6):3363-71
pubmed: 9920878
Biomolecules. 2014 Jun 19;4(2):566-84
pubmed: 24970231
Neoplasia. 2007 Nov;9(11):960-9
pubmed: 18030364
Mol Biol Cell. 2008 Apr;19(4):1706-16
pubmed: 18256291
Mol Cell. 2010 Oct 22;40(2):216-27
pubmed: 20965417
Nat Rev Immunol. 2012 Jul 13;12(8):557-69
pubmed: 22790179
Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7976-80
pubmed: 7644523
Genome Biol Evol. 2015 May 04;7(5):1363-79
pubmed: 25943340
Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):17951-6
pubmed: 24082107
Cell. 2006 Jan 27;124(2):381-92
pubmed: 16439211
Mol Cell. 2007 Jun 22;26(6):831-42
pubmed: 17588518
Biochemistry. 2002 Jun 4;41(22):7047-53
pubmed: 12033938
Cell Mol Life Sci. 2011 May;68(9):1491-502
pubmed: 21387144
Curr Opin Immunol. 2012 Feb;24(1):84-91
pubmed: 22206698
Proc Natl Acad Sci U S A. 2018 Jul 10;115(28):E6477-E6486
pubmed: 29934401
Eur J Cell Biol. 1998 Oct;77(2):151-60
pubmed: 9840465
J Immunol. 1993 Apr 1;150(7):2724-36
pubmed: 8454852
Nat Commun. 2013;4:2667
pubmed: 24157709
Cancer Immunol Immunother. 2008 Nov;57(11):1719-26
pubmed: 18408926
Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18599-604
pubmed: 20937868
Biochim Biophys Acta. 2014 Sep;1843(9):1942-7
pubmed: 24851840
J Immunol. 1996 Sep 1;157(5):1823-6
pubmed: 8757297
EMBO J. 2001 May 15;20(10):2357-66
pubmed: 11350924
Chem Biol. 2001 Aug;8(8):739-58
pubmed: 11514224
Biochimie. 2001 Mar-Apr;83(3-4):301-10
pubmed: 11295490
Annu Rev Biochem. 1996;65:801-47
pubmed: 8811196
Oncoimmunology. 2016 Jun 21;5(9):e1198865
pubmed: 27757298
Cancer Res. 2011 Feb 1;71(3):852-61
pubmed: 21156648
Arch Biochem Biophys. 2003 Jul 1;415(1):1-5
pubmed: 12801506
Immunity. 2000 Jan;12(1):107-17
pubmed: 10661410
EMBO J. 2008 Mar 19;27(6):852-64
pubmed: 18309296
Curr Opin Immunol. 2001 Apr;13(2):147-53
pubmed: 11228406
Nat Protoc. 2007;2(8):1896-906
pubmed: 17703201
J Immunol. 2004 Mar 15;172(6):3948-54
pubmed: 15004203
Oncotarget. 2016 May 31;7(22):31663-80
pubmed: 27203220
Mol Biol Cell. 2002 Aug;13(8):2771-82
pubmed: 12181345
Nat Rev Immunol. 2010 Jan;10(1):73-8
pubmed: 20010787
Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10850-5
pubmed: 9380723
Structure. 2009 Aug 12;17(8):1137-47
pubmed: 19679091
Cancer Res. 2008 May 15;68(10):3566-72
pubmed: 18483236
Annu Rev Biophys. 2013;42:29-49
pubmed: 23414347
Nat Immunol. 2004 Jun;5(6):606-14
pubmed: 15146180
PLoS One. 2013;8(2):e55583
pubmed: 23383339
Methods Enzymol. 2005;398:336-52
pubmed: 16275341
Immunol Rev. 2005 Oct;207:31-41
pubmed: 16181325
Chem Biol. 2014 Apr 24;21(4):470-480
pubmed: 24631123
Int J Biol Sci. 2011;7(6):805-14
pubmed: 21750649
Mol Cell. 2007 Jun 22;26(6):843-52
pubmed: 17588519
Nat Biotechnol. 2018 Dec;36(11):1056-1058
pubmed: 30114007
EMBO J. 2002 Jun 3;21(11):2636-45
pubmed: 12032076
Nature. 2000 Nov 2;408(6808):115-20
pubmed: 11081519
J Natl Cancer Inst. 2013 Aug 21;105(16):1172-87
pubmed: 23852952
Mol Cell. 2004 Nov 19;16(4):575-86
pubmed: 15546617
J Mol Endocrinol. 2011 Aug 03;47(1):119-27
pubmed: 21646385
J Immunol. 2000 Jun 15;164(12):6147-57
pubmed: 10843664
J Biol Chem. 2016 Jun 17;291(25):13147-59
pubmed: 27129254
Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12504-9
pubmed: 9770515
Proc Natl Acad Sci U S A. 2011 Jul 12;108(28):11572-7
pubmed: 21709220
BMC Cancer. 2012 Feb 23;12:75
pubmed: 22361172
Anal Chem. 2003 Feb 1;75(3):663-70
pubmed: 12585499
J Exp Med. 1996 Mar 1;183(3):1173-83
pubmed: 8642259
FEBS Lett. 1997 Aug 11;413(1):27-34
pubmed: 9287111
Cell. 2017 May 18;169(5):792-806
pubmed: 28525752

Auteurs

Mathilde Boulpicante (M)

Immunologie des Tumeurs et Immunothérapie, Université Paris-Saclay, Institut Gustave Roussy, Inserm, Villejuif, France.

Romain Darrigrand (R)

Immunologie des Tumeurs et Immunothérapie, Université Paris-Saclay, Institut Gustave Roussy, Inserm, Villejuif, France.

Alison Pierson (A)

Immunologie des Tumeurs et Immunothérapie, Université Paris-Saclay, Institut Gustave Roussy, Inserm, Villejuif, France.

Valérie Salgues (V)

Immunologie des Tumeurs et Immunothérapie, Université Paris-Saclay, Institut Gustave Roussy, Inserm, Villejuif, France.

Marine Rouillon (M)

Immunologie des Tumeurs et Immunothérapie, Université Paris-Saclay, Institut Gustave Roussy, Inserm, Villejuif, France.

Benoit Gaudineau (B)

Dynamique des Cellules Tumorales, Université Paris-Saclay, Institut Gustave Roussy, Inserm, Villejuif, France.

Mehdi Khaled (M)

Dynamique des Cellules Tumorales, Université Paris-Saclay, Institut Gustave Roussy, Inserm, Villejuif, France.

Angela Cattaneo (A)

IFOM, The FIRC Institute of Molecular Oncology, Milano, Italy.

Angela Bachi (A)

IFOM, The FIRC Institute of Molecular Oncology, Milano, Italy.

Paolo Cascio (P)

Department of Veterinary Sciences, University of Turin, 10095, Grugliasco, Turin, Italy.

Sébastien Apcher (S)

Immunologie des Tumeurs et Immunothérapie, Université Paris-Saclay, Institut Gustave Roussy, Inserm, Villejuif, France.

Articles similaires

The pore-forming apolipoprotein APOL7C drives phagosomal rupture and antigen cross-presentation by dendritic cells.

Gerone A Gonzales, Song Huang, Liam Wilkinson et al.
1.00
Dendritic Cells Animals Cross-Priming Mice Mice, Inbred C57BL

Ubiquitination regulates autophagy in cancer: simple modifications, promising targets.

Yihui Wu, Yifei Chen, Xianyan Tian et al.
1.00
Autophagy Humans Neoplasms Ubiquitination Animals

PRR adjuvants restrain high stability peptides presentation on APCs.

Bin Li, Jin Zhang, Taojun He et al.
1.00
Animals Adjuvants, Immunologic Mice Antigen-Presenting Cells Antigen Presentation

Tumour evolution and microenvironment interactions in 2D and 3D space.

Chia-Kuei Mo, Jingxian Liu, Siqi Chen et al.
1.00
Humans Tumor Microenvironment Neoplasms DNA Copy Number Variations Deep Learning

Classifications MeSH

questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Immunité acquise › Immunité cellulaire › Présentation d'antigène › Tumors escape immunosurveillance by...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Isoantigènes › Antigènes d'histocompatibilité › Antigènes d'histocompatibilité de classe I › Tumors escape immunosurveillance by...
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Tests immunologiques › Monitorage immunologique › Tumors escape immunosurveillance by...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Complexes multienzymatiques › Proteasome endopeptidase complex › Tumors escape immunosurveillance by...
questionsmedicales.fr › Phénomènes du système immunitaire › Échappement de la tumeur à la surveillance immunitaire › Tumors escape immunosurveillance by...